Novartis Investor Presentation

> New Novartis: Our strategy Our focus Our priorities Conclusion Abbreviations Focused Innovative Medicines company consistently delivering strong operational performance 2014 | Pre-portfolio transformation 2017 | Pre-Alcon spin-off +6% 42.0 AH Vx OTC 31.8 IM Sales Alcon USD billion, % CAGR CC Alcon Sandoz IM IM Sandoz FY 2016 FY 2021 + 10% 15.2 10.1 IM Core Oplnc 2019 Post-Alcon spin-off 2023 | Post-Sandoz spin-off USD billion, % CAGR CC FY 2016 FY 2021 Sandoz IM 4 Novartis Investor Presentation | September 22, 2022 IM 36.2% 31.6% IM Core Margin % FY 2016 FY 2021 1 | NOVARTIS | Reimagining Medicine

View entire presentation